Publikation:
Improving environmental protection in EU pharmaceutical legislation

Kurzanzeige
dc.contributor.authorGildemeister, Daniela
dc.contributor.authorBuck, Annika
dc.contributor.authorHein, Arne
dc.contributor.authorRönnefahrt, Ines
dc.contributor.authorEbert, Ina
dc.contributor.authorDebiak, Malgorzata
dc.date.accessioned2024-06-16T13:10:15Z
dc.date.available2024-06-16T13:10:15Z
dc.date.issued2022
dc.description.abstractIn preparation of the revision of Directive 2001/83/ EC and Regulation (EC) No 726/2004, the German Environment Agency (UBA) proposes legal changes to reduce pharmaceutical residues in the environment. The proposals are based on UBA's experiences as competent authority for the environmental risk assessment (ERA) of pharmaceuticals. Our overall aim is to ensure a comprehensive risk management system without compromising availability of medicines for patients. In this context we consider the recent EU strategy on pharmaceuticals and initiatives in connection with EU`s Green Deal particularly the Zero Pollution Ambition and the one substance one assessment approach. Quelle: www.umweltbundesamt.deen
dc.description.abstractIn preparation of the revision of Directive 2001/83/ EC and Regulation (EC) No 726/2004, the German Environment Agency (⁠UBA⁠) proposes legal changes to reduce pharmaceutical residues in the environment. The proposals are based on UBA’s experiences as competent authority for the environmental risk assessment (ERA) of pharmaceuticals. Our overall aim is to ensure a comprehensive risk management system without compromising availability of medicines for patients. In this context we consider the recent EU strategy on pharmaceuticals and initiatives in connection with EU`s Green Deal particularly the Zero Pollution Ambition and the one substance one assessment approach.en
dc.description.abstractIn preparation of the revision of Directive 2001/83/ EC and Regulation (EC) No 726/2004, the German Environment Agency (UBA) proposes legal changes to reduce pharmaceutical residues in the environment. The proposals are based on UBA’s experiences as competent authority for the environmental risk assessment (ERA) of pharmaceuticals. Our overall aim is to ensure a comprehensive risk management system without compromising availability of medicines for patients. In this context we consider the recent EU strategy on pharmaceuticals and initiatives in connection with EU`s Green Deal particularly the Zero Pollution Ambition and the one substance one assessment approach.en
dc.format.extent23
dc.format.mediumonline resource
dc.identifier.doihttps://doi.org/10.60810/openumwelt-3797
dc.identifier.urihttps://openumwelt.de/handle/123456789/2585
dc.language.isoeng
dc.publisherUmweltbundesamt
dc.relation.ispartofseriesScientific Opinion Paper
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/
dc.source.urihttp://www.umweltbundesamt.de/sites/default/files/medien/1410/publikationen/2022-10-26_sop_environmental-protection-eu-pharmaceutical-legislation_bf.pdf
dc.subjectUmweltrisikobewertung
dc.subjectpharmaceuticals
dc.subjectenvironmental risk assessment
dc.subject.ubaThemeChemicals
dc.subject.ubaThemeChemikalien
dc.subject.ubaThemeGesundheit
dc.subject.ubaThemeNachhaltigkeit | Strategien | Internationales
dc.subject.ubaThemeHealth
dc.subject.ubaThemeSustainability | Strategies | International matters
dc.titleImproving environmental protection in EU pharmaceutical legislationen
dc.typeMonographie
dc.type.dcmitext
dc.type.mediumcomputer
dspace.entity.typePublication
local.audiencePublic authorities
local.bibliographicCitation.publisherPlaceDessau-Roßlau
local.collectionScientific Opinion Paper
local.contributor.authorId02152711
local.contributor.authorId02190741
local.contributor.authorId02145607
local.contributor.authorId00362789
local.contributor.authorId02013344
local.contributor.authorId02163691
local.identifier.catalogId02493983
local.identifier.cmsId98506
local.ingest.cmsCreatedOn2022-10-13T15:44:46
local.ingest.cmsModifiedOn2024-08-19T17:03:04
local.ingest.cmsStateChangedOn2024-08-19T17:03:01
local.ingest.cmsStateNewLive (veröffentlicht)
local.ingest.cmsStateOldLive Überarbeitung
local.ingest.cmsStateRevisionId195549
local.ingest.leader05309nam a2200000uu 4500
local.ingest.needsManualMetadataChecktrue
local.jointTitleIMPROVING ENVIRONMENTAL PROTECTION IN EU PHARMACEUTICAL LEGISLATION RECOMMENDATIONS FOR REDUCING ADVERSE ENVIRONMENTAL IMPACTS FROM HUMAN PHARMACEUTICALS
local.newsletter0
local.sourcecatalog
local.sourceenriched with cms, Id: 98506 at 2024-06-18T15:38:30.316240
local.sourceupdated with CMS, Id: 98506 at 2024-10-09T09:19:51.211317
local.source.urihttp://www.umweltbundesamt.de/publikationen/improving-environmental-protection-in-eu
local.staffPublicationtrue
local.subtitleRecommendations for reducing adverse environmental impacts from human pharmaceuticalsen
Dateien
Originalbündel
Gerade angezeigt 1 - 1 von 1
Vorschaubild
Name:
2022-10-26_sop_environmental-protection-eu-pharmaceutical-legislation_bf.pdf
Größe:
1011.72 KB
Format:
Adobe Portable Document Format
Beschreibung:
2022-10-26_sop_environmental-protection-eu-pharmaceutical-legislation_bf.pdf, downloaded 2024-06-16T13:10:16.225655
Herunterladen
Sammlungen
Scientific Opinion Paper